Holen Sie sich die Stockscreener-App
5.95
2.41%
0.14
Handel nachbörslich:
6.00
0.05
+0.84%
Schlusskurs vom Vortag:
$5.81
Offen:
$5.81
24-Stunden-Volumen:
93,992
Relative Volume:
2.49
Marktkapitalisierung:
$342.08M
Einnahmen:
$154.57M
Nettoeinkommen (Verlust:
$15.07M
KGV:
74.38
EPS:
0.08
Netto-Cashflow:
$10.92M
1W Leistung:
-2.46%
1M Leistung:
+9.37%
6M Leistung:
+10.80%
1J Leistung:
+26.06%
1-Tages-Spanne:
$5.81
$6.115
1-Wochen-Bereich:
$5.759
$6.32
52-Wochen-Spanne:
$4.60
$6.5291
Kamada Ltd Stock (KMDA) Company Profile
Vergleichen Sie KMDA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| KMDA | 5.95 | 342.08M | 154.57M | 15.07M | 10.92M | 0.08 |
| ZTS | 176.42 | 79.51B | 9.15B | 2.43B | 2.31B | 4.92 |
| TAK | 13.53 | 42.89B | 30.27B | 1.93B | 3.45B | 0.444 |
| HLN | 9.43 | 42.57B | 14.26B | 1.55B | 0 | 0.3327 |
| TEVA | 16.49 | 18.51B | 16.77B | -959.00M | 1.37B | -2.00 |
| VTRS | 13.00 | 15.37B | 15.24B | -646.50M | 1.88B | 1.53 |
Kamada Ltd Stock (KMDA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2018-02-02 | Eingeleitet | Chardan Capital Markets | Buy |
Kamada Ltd Aktie (KMDA) Neueste Nachrichten
Alpha 1 Antitrypsin Deficiency Treatment Market Analysis By Top - openPR
What is HC Wainwright’s Forecast for Kamada FY2024 Earnings? - Defense World
Alpha-1 Antitrypsin Deficiency Therapy Market 2024-2031 - openPR
HC Wainwright Forecasts Kamada's Q4 Earnings (NASDAQ:KMDA) - MarketBeat
Earnings call: Kamada Ltd. reports growth and raises EBITDA outlook - Investing.com
Phoenix Financial Ltd. Increases Stake in Kamada Ltd. - GuruFocus.com
Kamada Ltd. (NASDAQ:KMDA) Q3 2024 Earnings Call Transcript - Insider Monkey
Kamada Ltd (KMDA) Q3 2024 Earnings Call Highlights: Strong Reven - GuruFocus.com
Kamada Ltd (KMDA) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Increased EBITDA ... - Yahoo Finance
Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market to Grow - openPR
Alpha-1 Antitrypsin Deficiency Market Expected to Experience Major Growth by 2034, According to DelveInsight | Kamada Pharma, Mereo BioPharma/AstraZeneca, Grifols Therapeutics LLC, Takeda, Vertex - Barchart
Kamada: Q3 Earnings Snapshot - Barchart
Kamada reports Q3 EPS 7c, consensus 7c - TipRanks
Kamada’s Strong Growth and Strategic Expansion in 2024 - TipRanks
KMDAKamada Ltd Latest Stock News & Market Updates - StockTitan
Kamada Reports Continued Profitable Growth with Strong Third Quarter and Nine Month 2024 Financial Results; Raises Full-Year Profitability Guidance - The Manila Times
Kamada Reports Continued Profitable Growth with Strong - GlobeNewswire
Kamada Q3 Revenue Surges 10% to $41.7M, Boosts EBITDA Guidance Amid Strong Growth | KMDA Stock News - StockTitan
Report shares who was actually responsible for bringing Daichi Kamada to Crystal Palace - We Are Palace
Alpha 1 Lung Disease Market Growth Set to Surge Significantly by 2031 As Revealed In New Report - WhaTech
What fixtures Daichi Kamada will miss for Crystal Palace after red card in 2-0 Fulham defeat - We Are Palace
Kamada (KMDA) Scheduled to Post Earnings on Wednesday - MarketBeat
Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore's HealthCONx Conference on December 5, 2024 - The Manila Times
Kamada Ltd. sets Q3 earnings call for November 13 - Investing.com India
Kamada to Release Q3 Financial Results Amid Global Expansion - TipRanks
Kamada to Announce Third Quarter and Nine-Months Ended September 30, 2024 Financial Results and Host Conference Call on November 13, 2024 - The Manila Times
Kamada to Announce Third Quarter and Nine-Months Ended - GlobeNewswire
Kamada (KMDA) Sets Q3 2024 Earnings Call for November 13What to Expect | KMDA Stock News - StockTitan
Stratasys unveils new IoT platform for 3D printing operations By Investing.com - Investing.com South Africa
Kamada to Present at the Stifel 2024 Healthcare Conference - GlobeNewswire
Kamada to Present at Stifel Healthcare Conference - TipRanks
Earnings growth outpaced the 24% return delivered to Kamada (TLV:KMDA) shareholders over the last year - Simply Wall St
Blood Plasma Market to Grow by USD 15.9 Billion (2024-2028) as Innovative Solutions Address Global Blood Shortage; Report Highlights AI's Impact on Market TrendsTechnavio - The Malaysian Reserve
Global Healthcare & Medical Tourism News - Medical Tourism Magazine
Global Plasma Protein Therapeutics Market to Touch ~USD 40 Billion Mark by 2030 | DelveInsight - GlobeNewswire
What Jean-Philippe Mateta did after Daichi Kamada scored in Aston Villa 1-2 Crystal Palace, it was telling - We Are Palace
Kamada strike secures Quarter-Final spot - Holmesdale Online
Aston Villa 1-2 Crystal Palace: Daichi Kamada fires Eagles into last eight of Carabao Cupbut visitors lose - Daily Mail
Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET - The Manila Times
Alvotech to Report Financial Results for the First Nine - GlobeNewswire
Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19-20, 2024 - The Manila Times
Alvotech Meeting Investors and Presenting at the Jefferies - GlobeNewswire
Kamada (NASDAQ:KMDA) Shares Cross Below Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Kamada Ltd. Announces 2024 Annual General Meeting - TipRanks
Alpha 1 Lung Disease Market Projected to Reach $19.93 Billion by 2031 with 19.33% CAGR - WhaTech
Kamada Ltd. (NASDAQ:KMDA) Short Interest Update - MarketBeat
Lower Respiratory Tract Therapeutics Global Market Advancements Highlighted by Size, Insights Forecast, Tre... - WhaTech
Alpha 1 Antitrypsin Deficiency Treatment Market Size Is Booming Worldwide with Share, Size, Top Key Players - La Funcion mx
Daichi Kamada says Japan can close in on World Cup place against Australia - Business Recorder
European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva® - The Manila Times
Kamada (NASDAQ:KMDA) Stock Crosses Below 200 Day Moving AverageShould You Sell? - MarketBeat
Finanzdaten der Kamada Ltd-Aktie (KMDA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.79%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):